Methotrexate for Rheumatoid Arthritis

Arthritis & Rheumatism

Volumn 37, Issue 3, 1994, Pages 316-328

  Kremer, Joel M ^a   Alarcón, Graciela S ^b   Lightfoot, Robert W ^c   Willkens, Robert F ^d   Furst, Daniel E ^e   Williams, H James ^f   Dent, Peter B ^g   Weinblatt, Michael E ^h  

^a ALBANY MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e VIRGINIA MASON MEDICAL CENTER   (United States)

^f UNIVERSITY OF UTAH   (United States)

^g MCMASTER UNIVERSITY   (Canada)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; AURANOFIN; BILIRUBIN; METHOTREXATE;

ARTICLE; BLOOD CELL COUNT; COST BENEFIT ANALYSIS; CREATININE BLOOD LEVEL; HEPATITIS B; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER DISEASE; LIVER FUNCTION TEST; LIVER TOXICITY; PATIENT MONITORING; PATIENT SELECTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR;

ARTHRITIS, RHEUMATOID; BIOPSY; COSTS AND COST ANALYSIS; HUMANS; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; METHOTREXATE; RISK FACTORS;

EID: 0028215036     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.1780370304     Document Type: Article

References (63)

1. Methotrexate in rheumatoid arthritis (abstract)
2. Methotrexate therapy in rheumatoid arthritis: 15 years experience
3. Methotrexate: a perspective of its use in the treatment of rheumatic diseases
4. Low dose methotrexate in rheumatoid arthritis
5. Efficacy of low‐dose methotrexate in rheumatoid arthritis
6. Comparison of low‐dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial
7. A controlled two‐centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis
8. Weekly pulse methotrexate in rheumatoid arthritis: clinical and immunologic effects in a randomized, double‐blind study
9. Low‐dose methotrexate compared with azathioprine in the treatment of rheumatoid arthritis: a twenty‐four–week controlled clinical trial
10. Comparative controlled trial of low‐dose weekly methotrexate versus azathioprine in rheumatoid arthritis: 3‐year prospective study
11. Gold sodium thiomalate compared to low dose methotrexate in the treatment of rheumatoid arthritis: a randomized, double blind 26‐week trial
12. A randomized controlled trial of parenteral methotrexate compared with sodium aurothiomalate (Myochrysine) in the treatment of rheumatoid arthritis
13. Low‐dose methotrexate compared with auranofin in adult rheumatoid arthritis: a thirty‐six–week, double‐blind trial
14. A double blind randomized parallel trial of intramuscular methotrexate and gold sodium thiomalate in early erosive rheumatoid arthritis
15. Methotrexate versus azathioprine in the treatment of rheumatoid arthritis: a forty‐eight–week randomized, doubleblind trial
16. The safety and efficacy of the use of methotrexate in long‐term therapy for rheumatoid arthritis
17. A long‐term prospective study of the use of methotrexate in rheumatoid arthritis: update after a mean of fifty‐three months
18. Long‐term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis: update after a mean of 90 months
19. Methotrexate in rheumatoid arthritis: effects on disease activity in a multicenter prospective study
20. Prospective long term follow‐up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression
21. Long‐term prospective trial of low‐dose methotrexate in rheumatoid arthritis
22. Long‐term prospective study of methotrexate in the treatment of rheumatoid arthritis: 84‐month update
23. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14‐year prospective evaluation of 1017 consecutive starts
24. Methotrexate in rheumatoid arthritis: toxic effects as the major factor in limiting long‐term treatment
25. Methotrexate guidelines: revised
26. Methotrexate in psoriasis: revised guidelines
27. Methotrexate in rheumatoid arthritis
28. Methotrexate in rheumatoid arthritis
29. Methotrexateinduced liver abnormalities in rheumatoid arthritis
30. Liver biopsies in patients with rheumatoid arthritis receiving methotrexate: where are we going
31. Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis
32. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis
33. Pretreatment liver histology in rheumatoid arthritis patients treated with low dose methotrexate (abstract)
34. Liver histology in rheumatoid arthritis patients receiving long‐term methotrexate therapy: a prospective study with baseline and sequential biopsy samples
35. Baseline and follow‐up liver histology in rheumatoid arthritis patients receiving pulse methotrexate (abstract)
36. Low‐dose weekly oral methotrexate therapy for inflammatory arthritis
37. Prospective analysis of liver biopsies before and after methotrexate therapy in rheumatoid patients
38. Liver biopsy findings in patients with rheumatoid arthritis undergoing longterm treatment with methotrexate
39. Liver histology in rheumatoid arthritis before and after prolonged methotrexate therapy (abstract)
40. Clinical liver disease in patients with rheumatoid arthritis taking methotrexate
41. The Sentinel Counties Chronic Non‐A Non‐B Hepatitis Study Team: The natural history of community acquired hepatitis C in the United States
42. Progress report natural history of the HBsAg carrier
43. Low‐dose methotrexate treatment of rheumatoid arthritis: long‐term observations
44. Liver histology in patients receiving low dose pulse methotrexate for the treatment of rheumatoid arthritis
45. Methotrexate‐associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis
46. Long‐term prospective sequential liver biopsies in patients with rheumatoid arthritis on weekly oral methotrexate (abstract)
47. Histopathologic findings in the liver of rheumatoid arthritis patients treated with long‐term bolus methotrexate
48. Methotrexate and the liver
49. Hepatotoxicity associated with low‐dose, long‐term methotrexate treatment of rheumatoid arthritis
50. Serial liver biopsies from methotrexate‐treated rheumatoid arthritis patients (abstract)
51. Electron microscopic analysis of sequential liver biopsy samples from patients with rheumatoid arthritis: correlation with light microscopic findings
52. Acute, reversible hepatic failure associated with methotrexate treatment of rheumatoid arthritis
53. Hepatitis with bridging fibrosis and reversible hepatic insufficiency in a woman with rheumatoid arthritis taking methotrexate
54. Prospective study of hepatotoxicity in patients receiving methotrexate for rheumatoid arthritis (abstract)
55. Determinants of serious liver disease among patients receiving low‐dose methotrexate for rheumatoid arthritis
56. Methotrexate and histologic hepatic abnormalities: a meta‐analysis
57. Psoriasis‐liver‐methotrexate interactions
58. Liver biopsies from psoriatics related to methotrexate therapy: 3. Findings in post‐methotrexate liver biopsies from 160 psoriatics
59. Methotrexate induced liver cirrhosis: studies including serial liver biopsies during continued treatment
60. Outpatient liver biopsy: how safe is it
61. The cost‐effectiveness of liver biopsy in rheumatoid arthritis patients on methotrexate (abstract)
62. Complications following percutaneous liver biopsy: a multicentre retrospective study on 68,276 biopsies